▶ 調査レポート

CD47(IAP)のグローバル市場インサイト・予測(~2028年)

• 英文タイトル:Global CD47 (IAP) Market Insights, Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。CD47(IAP)のグローバル市場インサイト・予測(~2028年) / Global CD47 (IAP) Market Insights, Forecast to 2028 / QY2207C3850資料のイメージです。• レポートコード:QY2207C3850
• 出版社/出版日:QYResearch / 2022年7月11日
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥646,800 (USD4,900)▷ お問い合わせ
  Multi User¥970,200 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,293,600 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界のCD47(IAP)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にCD47(IAP)の世界市場のxxx%を占める「CD47モノクローナル抗体」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「固形腫瘍」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国のCD47(IAP)の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのCD47(IAP)市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのCD47(IAP)市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

CD47(IAP)のグローバル主要メーカーには、Gilead、Innovent Biologics、Akeso, Inc、Arch Oncology、ImmuneOncia Therapeutics、I-MAB、Sorrento Therapeutics、Zai Lab、ImmuneOnco、Hengrui、Beijing Mab-works、Hanxbio、ALX Oncology、Surface Oncology、TG Therapeutics、EpicentRxなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

CD47(IAP)市場は、種類と用途によって区分されます。世界のCD47(IAP)市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
CD47モノクローナル抗体、CD47ダブル抗体、CD47融合タンパク質

【用途別セグメント】
固形腫瘍、リンパ腫、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- CD47(IAP)製品概要
- 種類別市場(CD47モノクローナル抗体、CD47ダブル抗体、CD47融合タンパク質)
- 用途別市場(固形腫瘍、リンパ腫、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のCD47(IAP)販売量予測2017-2028
- 世界のCD47(IAP)売上予測2017-2028
- CD47(IAP)の地域別販売量
- CD47(IAP)の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別CD47(IAP)販売量
- 主要メーカー別CD47(IAP)売上
- 主要メーカー別CD47(IAP)価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(CD47モノクローナル抗体、CD47ダブル抗体、CD47融合タンパク質)
- CD47(IAP)の種類別販売量
- CD47(IAP)の種類別売上
- CD47(IAP)の種類別価格
・用途別市場規模(固形腫瘍、リンパ腫、その他)
- CD47(IAP)の用途別販売量
- CD47(IAP)の用途別売上
- CD47(IAP)の用途別価格
・北米市場
- 北米のCD47(IAP)市場規模(種類別、用途別)
- 主要国別のCD47(IAP)市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのCD47(IAP)市場規模(種類別、用途別)
- 主要国別のCD47(IAP)市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のCD47(IAP)市場規模(種類別、用途別)
- 主要国別のCD47(IAP)市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のCD47(IAP)市場規模(種類別、用途別)
- 主要国別のCD47(IAP)市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのCD47(IAP)市場規模(種類別、用途別)
- 主要国別のCD47(IAP)市場規模(トルコ、サウジアラビア)
・企業情報
Gilead、Innovent Biologics、Akeso, Inc、Arch Oncology、ImmuneOncia Therapeutics、I-MAB、Sorrento Therapeutics、Zai Lab、ImmuneOnco、Hengrui、Beijing Mab-works、Hanxbio、ALX Oncology、Surface Oncology、TG Therapeutics、EpicentRx
・産業チェーン及び販売チャネル分析
- CD47(IAP)の産業チェーン分析
- CD47(IAP)の原材料
- CD47(IAP)の生産プロセス
- CD47(IAP)の販売及びマーケティング
- CD47(IAP)の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- CD47(IAP)の産業動向
- CD47(IAP)のマーケットドライバー
- CD47(IAP)の課題
- CD47(IAP)の阻害要因
・主な調査結果

Market Analysis and Insights: Global CD47 (IAP) Market
The global CD47 (IAP) market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Solid Tumor segment is altered to an % CAGR throughout this forecast period.
China CD47 (IAP) market size is valued at US$ million in 2021, while the North America and Europe CD47 (IAP) are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe CD47 (IAP) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CD47 (IAP) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CD47 (IAP) market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CD47 (IAP) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CD47 (IAP) market.
Global CD47 (IAP) Scope and Market Size
CD47 (IAP) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Segment by Application
Solid Tumor
Lymphoma
Others
By Company
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD47 (IAP) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CD47 Monoclonal Antibody
1.2.3 CD47 Double Antibody
1.2.4 CD47 Fusion Protein
1.3 Market by Application
1.3.1 Global CD47 (IAP) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Solid Tumor
1.3.3 Lymphoma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global CD47 (IAP) Market Perspective (2017-2028)
2.2 CD47 (IAP) Growth Trends by Region
2.2.1 CD47 (IAP) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 CD47 (IAP) Historic Market Size by Region (2017-2022)
2.2.3 CD47 (IAP) Forecasted Market Size by Region (2023-2028)
2.3 CD47 (IAP) Market Dynamics
2.3.1 CD47 (IAP) Industry Trends
2.3.2 CD47 (IAP) Market Drivers
2.3.3 CD47 (IAP) Market Challenges
2.3.4 CD47 (IAP) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD47 (IAP) Players by Revenue
3.1.1 Global Top CD47 (IAP) Players by Revenue (2017-2022)
3.1.2 Global CD47 (IAP) Revenue Market Share by Players (2017-2022)
3.2 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD47 (IAP) Revenue
3.4 Global CD47 (IAP) Market Concentration Ratio
3.4.1 Global CD47 (IAP) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD47 (IAP) Revenue in 2021
3.5 CD47 (IAP) Key Players Head office and Area Served
3.6 Key Players CD47 (IAP) Product Solution and Service
3.7 Date of Enter into CD47 (IAP) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD47 (IAP) Breakdown Data by Type
4.1 Global CD47 (IAP) Historic Market Size by Type (2017-2022)
4.2 Global CD47 (IAP) Forecasted Market Size by Type (2023-2028)
5 CD47 (IAP) Breakdown Data by Application
5.1 Global CD47 (IAP) Historic Market Size by Application (2017-2022)
5.2 Global CD47 (IAP) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America CD47 (IAP) Market Size (2017-2028)
6.2 North America CD47 (IAP) Market Size by Type
6.2.1 North America CD47 (IAP) Market Size by Type (2017-2022)
6.2.2 North America CD47 (IAP) Market Size by Type (2023-2028)
6.2.3 North America CD47 (IAP) Market Share by Type (2017-2028)
6.3 North America CD47 (IAP) Market Size by Application
6.3.1 North America CD47 (IAP) Market Size by Application (2017-2022)
6.3.2 North America CD47 (IAP) Market Size by Application (2023-2028)
6.3.3 North America CD47 (IAP) Market Share by Application (2017-2028)
6.4 North America CD47 (IAP) Market Size by Country
6.4.1 North America CD47 (IAP) Market Size by Country (2017-2022)
6.4.2 North America CD47 (IAP) Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe CD47 (IAP) Market Size (2017-2028)
7.2 Europe CD47 (IAP) Market Size by Type
7.2.1 Europe CD47 (IAP) Market Size by Type (2017-2022)
7.2.2 Europe CD47 (IAP) Market Size by Type (2023-2028)
7.2.3 Europe CD47 (IAP) Market Share by Type (2017-2028)
7.3 Europe CD47 (IAP) Market Size by Application
7.3.1 Europe CD47 (IAP) Market Size by Application (2017-2022)
7.3.2 Europe CD47 (IAP) Market Size by Application (2023-2028)
7.3.3 Europe CD47 (IAP) Market Share by Application (2017-2028)
7.4 Europe CD47 (IAP) Market Size by Country
7.4.1 Europe CD47 (IAP) Market Size by Country (2017-2022)
7.4.2 Europe CD47 (IAP) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD47 (IAP) Market Size (2017-2028)
8.2 Asia-Pacific CD47 (IAP) Market Size by Type
8.2.1 Asia-Pacific CD47 (IAP) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific CD47 (IAP) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific CD47 (IAP) Market Share by Type (2017-2028)
8.3 Asia-Pacific CD47 (IAP) Market Size by Application
8.3.1 Asia-Pacific CD47 (IAP) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific CD47 (IAP) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific CD47 (IAP) Market Share by Application (2017-2028)
8.4 Asia-Pacific CD47 (IAP) Market Size by Region
8.4.1 Asia-Pacific CD47 (IAP) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific CD47 (IAP) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America CD47 (IAP) Market Size (2017-2028)
9.2 Latin America CD47 (IAP) Market Size by Type
9.2.1 Latin America CD47 (IAP) Market Size by Type (2017-2022)
9.2.2 Latin America CD47 (IAP) Market Size by Type (2023-2028)
9.2.3 Latin America CD47 (IAP) Market Share by Type (2017-2028)
9.3 Latin America CD47 (IAP) Market Size by Application
9.3.1 Latin America CD47 (IAP) Market Size by Application (2017-2022)
9.3.2 Latin America CD47 (IAP) Market Size by Application (2023-2028)
9.3.3 Latin America CD47 (IAP) Market Share by Application (2017-2028)
9.4 Latin America CD47 (IAP) Market Size by Country
9.4.1 Latin America CD47 (IAP) Market Size by Country (2017-2022)
9.4.2 Latin America CD47 (IAP) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD47 (IAP) Market Size (2017-2028)
10.2 Middle East & Africa CD47 (IAP) Market Size by Type
10.2.1 Middle East & Africa CD47 (IAP) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa CD47 (IAP) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa CD47 (IAP) Market Share by Type (2017-2028)
10.3 Middle East & Africa CD47 (IAP) Market Size by Application
10.3.1 Middle East & Africa CD47 (IAP) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa CD47 (IAP) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa CD47 (IAP) Market Share by Application (2017-2028)
10.4 Middle East & Africa CD47 (IAP) Market Size by Country
10.4.1 Middle East & Africa CD47 (IAP) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa CD47 (IAP) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Details
11.1.2 Gilead Business Overview
11.1.3 Gilead CD47 (IAP) Introduction
11.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
11.1.5 Gilead Recent Developments
11.2 Innovent Biologics
11.2.1 Innovent Biologics Company Details
11.2.2 Innovent Biologics Business Overview
11.2.3 Innovent Biologics CD47 (IAP) Introduction
11.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
11.2.5 Innovent Biologics Recent Developments
11.3 Akeso, Inc
11.3.1 Akeso, Inc Company Details
11.3.2 Akeso, Inc Business Overview
11.3.3 Akeso, Inc CD47 (IAP) Introduction
11.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
11.3.5 Akeso, Inc Recent Developments
11.4 Arch Oncology
11.4.1 Arch Oncology Company Details
11.4.2 Arch Oncology Business Overview
11.4.3 Arch Oncology CD47 (IAP) Introduction
11.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.4.5 Arch Oncology Recent Developments
11.5 ImmuneOncia Therapeutics
11.5.1 ImmuneOncia Therapeutics Company Details
11.5.2 ImmuneOncia Therapeutics Business Overview
11.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
11.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.5.5 ImmuneOncia Therapeutics Recent Developments
11.6 I-MAB
11.6.1 I-MAB Company Details
11.6.2 I-MAB Business Overview
11.6.3 I-MAB CD47 (IAP) Introduction
11.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
11.6.5 I-MAB Recent Developments
11.7 Sorrento Therapeutics
11.7.1 Sorrento Therapeutics Company Details
11.7.2 Sorrento Therapeutics Business Overview
11.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
11.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.7.5 Sorrento Therapeutics Recent Developments
11.8 Zai Lab
11.8.1 Zai Lab Company Details
11.8.2 Zai Lab Business Overview
11.8.3 Zai Lab CD47 (IAP) Introduction
11.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
11.8.5 Zai Lab Recent Developments
11.9 ImmuneOnco
11.9.1 ImmuneOnco Company Details
11.9.2 ImmuneOnco Business Overview
11.9.3 ImmuneOnco CD47 (IAP) Introduction
11.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
11.9.5 ImmuneOnco Recent Developments
11.10 Hengrui
11.10.1 Hengrui Company Details
11.10.2 Hengrui Business Overview
11.10.3 Hengrui CD47 (IAP) Introduction
11.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
11.10.5 Hengrui Recent Developments
11.11 Beijing Mab-works
11.11.1 Beijing Mab-works Company Details
11.11.2 Beijing Mab-works Business Overview
11.11.3 Beijing Mab-works CD47 (IAP) Introduction
11.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
11.11.5 Beijing Mab-works Recent Developments
11.12 Hanxbio
11.12.1 Hanxbio Company Details
11.12.2 Hanxbio Business Overview
11.12.3 Hanxbio CD47 (IAP) Introduction
11.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
11.12.5 Hanxbio Recent Developments
11.13 ALX Oncology
11.13.1 ALX Oncology Company Details
11.13.2 ALX Oncology Business Overview
11.13.3 ALX Oncology CD47 (IAP) Introduction
11.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.13.5 ALX Oncology Recent Developments
11.14 Surface Oncology
11.14.1 Surface Oncology Company Details
11.14.2 Surface Oncology Business Overview
11.14.3 Surface Oncology CD47 (IAP) Introduction
11.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
11.14.5 Surface Oncology Recent Developments
11.15 TG Therapeutics
11.15.1 TG Therapeutics Company Details
11.15.2 TG Therapeutics Business Overview
11.15.3 TG Therapeutics CD47 (IAP) Introduction
11.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
11.15.5 TG Therapeutics Recent Developments
11.16 EpicentRx
11.16.1 EpicentRx Company Details
11.16.2 EpicentRx Business Overview
11.16.3 EpicentRx CD47 (IAP) Introduction
11.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
11.16.5 EpicentRx Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global CD47 (IAP) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of CD47 Monoclonal Antibody
Table 3. Key Players of CD47 Double Antibody
Table 4. Key Players of CD47 Fusion Protein
Table 5. Global CD47 (IAP) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global CD47 (IAP) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global CD47 (IAP) Market Share by Region (2017-2022)
Table 9. Global CD47 (IAP) Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global CD47 (IAP) Market Share by Region (2023-2028)
Table 11. CD47 (IAP) Market Trends
Table 12. CD47 (IAP) Market Drivers
Table 13. CD47 (IAP) Market Challenges
Table 14. CD47 (IAP) Market Restraints
Table 15. Global CD47 (IAP) Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global CD47 (IAP) Revenue Share by Players (2017-2022)
Table 17. Global Top CD47 (IAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021)
Table 18. Ranking of Global Top CD47 (IAP) Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by CD47 (IAP) Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players CD47 (IAP) Product Solution and Service
Table 22. Date of Enter into CD47 (IAP) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global CD47 (IAP) Revenue Market Share by Type (2017-2022)
Table 26. Global CD47 (IAP) Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global CD47 (IAP) Revenue Market Share by Type (2023-2028)
Table 28. Global CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global CD47 (IAP) Revenue Share by Application (2017-2022)
Table 30. Global CD47 (IAP) Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global CD47 (IAP) Revenue Share by Application (2023-2028)
Table 32. North America CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America CD47 (IAP) Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America CD47 (IAP) Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe CD47 (IAP) Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe CD47 (IAP) Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific CD47 (IAP) Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific CD47 (IAP) Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific CD47 (IAP) Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America CD47 (IAP) Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America CD47 (IAP) Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa CD47 (IAP) Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa CD47 (IAP) Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa CD47 (IAP) Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa CD47 (IAP) Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa CD47 (IAP) Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa CD47 (IAP) Market Size by Country (2023-2028) & (US$ Million)
Table 62. Gilead Company Details
Table 63. Gilead Business Overview
Table 64. Gilead CD47 (IAP) Product
Table 65. Gilead Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 66. Gilead Recent Developments
Table 67. Innovent Biologics Company Details
Table 68. Innovent Biologics Business Overview
Table 69. Innovent Biologics CD47 (IAP) Product
Table 70. Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 71. Innovent Biologics Recent Developments
Table 72. Akeso, Inc Company Details
Table 73. Akeso, Inc Business Overview
Table 74. Akeso, Inc CD47 (IAP) Product
Table 75. Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 76. Akeso, Inc Recent Developments
Table 77. Arch Oncology Company Details
Table 78. Arch Oncology Business Overview
Table 79. Arch Oncology CD47 (IAP) Product
Table 80. Arch Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 81. Arch Oncology Recent Developments
Table 82. ImmuneOncia Therapeutics Company Details
Table 83. ImmuneOncia Therapeutics Business Overview
Table 84. ImmuneOncia Therapeutics CD47 (IAP) Product
Table 85. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 86. ImmuneOncia Therapeutics Recent Developments
Table 87. I-MAB Company Details
Table 88. I-MAB Business Overview
Table 89. I-MAB CD47 (IAP) Product
Table 90. I-MAB Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 91. I-MAB Recent Developments
Table 92. Sorrento Therapeutics Company Details
Table 93. Sorrento Therapeutics Business Overview
Table 94. Sorrento Therapeutics CD47 (IAP) Product
Table 95. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 96. Sorrento Therapeutics Recent Developments
Table 97. Zai Lab Company Details
Table 98. Zai Lab Business Overview
Table 99. Zai Lab CD47 (IAP) Product
Table 100. Zai Lab Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 101. Zai Lab Recent Developments
Table 102. ImmuneOnco Company Details
Table 103. ImmuneOnco Business Overview
Table 104. ImmuneOnco CD47 (IAP) Product
Table 105. ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 106. ImmuneOnco Recent Developments
Table 107. Hengrui Company Details
Table 108. Hengrui Business Overview
Table 109. Hengrui CD47 (IAP) Product
Table 110. Hengrui Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 111. Hengrui Recent Developments
Table 112. Beijing Mab-works Company Details
Table 113. Beijing Mab-works Business Overview
Table 114. Beijing Mab-works CD47 (IAP) Product
Table 115. Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 116. Beijing Mab-works Recent Developments
Table 117. Hanxbio Company Details
Table 118. Hanxbio Business Overview
Table 119. Hanxbio CD47 (IAP) Product
Table 120. Hanxbio Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 121. Hanxbio Recent Developments
Table 122. ALX Oncology Company Details
Table 123. ALX Oncology Business Overview
Table 124. ALX Oncology CD47 (IAP) Product
Table 125. ALX Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 126. ALX Oncology Recent Developments
Table 127. Surface Oncology Company Details
Table 128. Surface Oncology Business Overview
Table 129. Surface Oncology CD47 (IAP) Product
Table 130. Surface Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 131. Surface Oncology Recent Developments
Table 132. TG Therapeutics Company Details
Table 133. TG Therapeutics Business Overview
Table 134. TG Therapeutics CD47 (IAP) Product
Table 135. TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 136. TG Therapeutics Recent Developments
Table 137. EpicentRx Company Details
Table 138. EpicentRx Business Overview
Table 139. EpicentRx CD47 (IAP) Product
Table 140. EpicentRx Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
Table 141. EpicentRx Recent Developments
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD47 (IAP) Market Share by Type: 2021 VS 2028
Figure 2. CD47 Monoclonal Antibody Features
Figure 3. CD47 Double Antibody Features
Figure 4. CD47 Fusion Protein Features
Figure 5. Global CD47 (IAP) Market Share by Application: 2021 VS 2028
Figure 6. Solid Tumor Case Studies
Figure 7. Lymphoma Case Studies
Figure 8. Others Case Studies
Figure 9. CD47 (IAP) Report Years Considered
Figure 10. Global CD47 (IAP) Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global CD47 (IAP) Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global CD47 (IAP) Market Share by Region: 2021 VS 2028
Figure 13. Global CD47 (IAP) Market Share by Players in 2021
Figure 14. Global Top CD47 (IAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by CD47 (IAP) Revenue in 2021
Figure 16. North America CD47 (IAP) Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America CD47 (IAP) Market Size Market Share by Type (2017-2028)
Figure 18. North America CD47 (IAP) Market Size Market Share by Application (2017-2028)
Figure 19. North America CD47 (IAP) Market Size Share by Country (2017-2028)
Figure 20. United States CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe CD47 (IAP) Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe CD47 (IAP) Market Size Market Share by Type (2017-2028)
Figure 24. Europe CD47 (IAP) Market Size Market Share by Application (2017-2028)
Figure 25. Europe CD47 (IAP) Market Size Share by Country (2017-2028)
Figure 26. Germany CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific CD47 (IAP) Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific CD47 (IAP) Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific CD47 (IAP) Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific CD47 (IAP) Market Size Share by Region (2017-2028)
Figure 36. China CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America CD47 (IAP) Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America CD47 (IAP) Market Size Market Share by Type (2017-2028)
Figure 44. Latin America CD47 (IAP) Market Size Market Share by Application (2017-2028)
Figure 45. Latin America CD47 (IAP) Market Size Share by Country (2017-2028)
Figure 46. Mexico CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa CD47 (IAP) Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa CD47 (IAP) Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa CD47 (IAP) Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa CD47 (IAP) Market Size Share by Country (2017-2028)
Figure 52. Turkey CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE CD47 (IAP) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Gilead Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 56. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 57. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 58. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 59. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 60. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 61. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 62. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 63. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 64. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 65. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 66. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 67. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 68. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 69. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 70. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed